In Brief: Oncologic Drugs Advisory Committee

Executive Summary

Oncologic Drugs Advisory Committee: At its June 8-9 meeting, the committee will review Rhone-Poulenc Rorer's Taxotere (docetaxel) for patients with locally advanced or metastatic breast carcinoma in whom previous therapy has failed and NeXstar's liposomal daunorubicin DaunoXome on June 8 ("The Pink Sheet" April 17, T&G-1). The committee recommended against approval of Taxotere based on Phase II data Dec. 12 ("The Pink Sheet" Dec. 19, 1994, p. 7). On June 9, the committee will review U.S. Bioscience's Ethyol (amifostine injection) for the cumulative renal toxicity associated with cisplatin and the cumulative hematologic toxicity of cyclophosphamide and cisplatin. The committee found the drug needed further study in recommending against approval Dec. 12 at Ethyol's second advisory committee review ("The Pink Sheet" Dec. 19, 1994, p. 11)...